Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits

Atherosclerosis

Volumn 172, Issue 2, 2004, Pages 247-257

  Shimoji, Eiso ^a   Zhang, Bo ^a   Fan, Ping ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Apolipoprotein (apo) A I; Cholesteryl ester transfer protein (CETP); High density lipoprotein (HDL); In vivo kinetics; mRNA levels; Rabbits

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; IODINE 125; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CATABOLISM; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; INTESTINE; KINETICS; LIPOPROTEIN METABOLISM; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RABBIT; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

EID: 0842303099     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.09.029     Document Type: Article

References (63)

1. Castelli W.P. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can. J. Cardiol. 4 Suppl A:1988;5A-I 10A.
2. Bucher H.C., Griffith L.E., Guyatt G.H. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 19:1999;187-195.
3. Vega G.L., Grundy S.M. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch. Intern. Med. 154:1994;73-82.
4. Tall A.R. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J. Intern. Med. 237:1995;5-12.
5. Saku K., Zhang B., Ohta T., Arakawa K. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J. Am. Coll. Cardiol. 33:1999;436-443.
6. Navab M., Berliner J.A., Subbanagounder G., Hama S., Lusis A.J., Castellani L.W.et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 21:2001;481-488.
7. Paszty C., Maeda N., Verstuyft J., Rubin E.M. Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin Invest. 94:1994;899-903.
8. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9607-9611.
9. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature. 353:1991;265-267.
10. Saku K., Gartside P.S., Hynd B.A., Kashyap M.L. Mechanism of action of gemfibrozil on lipoprotein metabolism. J. Clin. Invest. 75:1985;1702-1712.
11. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P.et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317:1987;1237-1245.
12. Huang Z., lnazu A., Nohara A., Higashikata T., Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (London). 103:2002;587-594.
13. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L.et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2002;2159-2165.
14. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
15. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B.et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl. J. Med. 341:1999;410-418.
16. Tall A.R. An overview of reverse cholesterol transport. Eur. Heart J. 19 Suppl A:1998;A31-A35.
17. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:1993;73-75.
18. Foger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B.et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274:1999;36912-36920.
19. Melchior G.W., Castle C.K., Murray R.W., Blake W.L., Dinh D.M., Marotti K.R. Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels. J. Biol. Chem. 269:1994;8044-8051.
20. Hayek T., Azrolan N., Verdery R.B., Walsh A., Chajek-Shaul T., Agellon L.B.et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. J. Clin Invest. 92:1993;1143-1152.
21. Rittershaus C.W., Miller D.P., Thomas U., Picard M.D., Honan C.M., Emmett C.D.et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc. Biol. 20:2000;2106-2112.
22. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H.et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:1998;5033-5036.
23. von Eckardstein A., Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr. Opin. Lipidol. 11:2000;627-637.
24. Kastelein J.J., lsaacsohn J.L., Ose L., Hunninghake D.B., Frohlich J., Davidson M.H.et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am. J. Cardiol. 86:2000;221-223.
25. Rashid S., Uffelman K.D., Barrett P.H., Lewis G.F. Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit. Circulation. 106:2002;2955-2960.
26. Sawada S., Sugano M., Makino N., Okamoto H., Tsuchida K. Secretion of prebeta HDL increases with the suppression of cholesteryl ester transfer protein in Hep G2 cells. Atherosclerosis. 146:1999;291-298.
27. Jayo JM, Schwenke DC, Clarkson TB. Aterosclerosis research. In: Manning PJ, Ringler GH, Newcomer CE, editors. The biology of the laboratory rabbit. San Diego: Academic Press; 1994. p. 367-80.
28. Zhang B., Saku K., Hirata K., Liu R., Tateishi K., Shiomi M.et al. Quantitative characterization of insulin-glucose response in Watanabe heritable hyperlipidemic and cholesterol-fed rabbits and the effect of cilazapril. Metabolism. 43:1994;360-366.
29. Zhang B., Fan P., Tanaka H., Saku K. Angiotensin II type-I receptor antagonist, CS-866, reduces blood pressure without affecting glucose/insulin metabolism in cholesterol-fed rabbits. Br. J. Biomed. Sci. 58:2001;217-225.
30. Zhang B., Shimoji E., Tanaka H., Keijiro S. Evaluation of apolipoprotein A-I kinetics in rabbits in vivo using in situ and exogenous radioiodination methods. Lipids. 38:2003;209-218.
31. Kwon M.J., Song Y.S., Choi M.S., Park S.J., Jeong K.S., Song Y.O. Cholesteryl ester transfer protein activity and atherogenic parameters in rabbits supplemented with cholesterol and garlic powder. Life Sci. 72:2003;2953-2964.
32. Okamoto H., Iwamoto Y., Maki M., Sotani T., Yonemori F., Wakitani K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur. J. Pharmacol. 466:2003;147-154.
33. Vega G.L., Gylling H., Nichols A.V., Grundy S.M. Evaluation of a method for study of kinetics of autologous apolipoprotein A-I. J. Lipid Res. 32:1991;867-875.
34. Nichols A.V., Gong E.L., Blanche P.J., Forte T.M., Anderson D.W. Effects of guanidine hydrochloride on human plasma high density lipoproteins. Biochim. Biophys. Acta. 446:1976;226-239.
35. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
36. Goldstein J.L., Basu S.K., Brown M.S. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98:1985;241-260.
37. Bilheimer D.W., Eisenberg S., Levy R.I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260:1972;212-221.
38. McFarlane A.S. Efficient trace-labelling of proteins with iodine. Nature. 182:1958;53.
39. Brousseau M.E., Santamarina-Fojo S., Zech L.A., Berard A.M., Vaisman B.L., Meyn S.M.et al. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J. Clin Invest. 97:1996;1844-1851.
40. Saku K., von Eckardstein A., Zhang B., Liu R., Jimi S., Ou J.et al., In vivo kinetics of human apolipoprotein A-I variants in rabbits Eur. J. Clin Invest. 29:1999;196-203.
41. Saku K., Liu R., Ohkubo K., Bai H., Hirata K., Yamamoto K.et al. In vivo conversion of recombinant human proapolipoprotein Al (rh-Met-proapo Al) to apolipoprotein Al in rabbits. Biochim. Biophys. Acta. 1167:1993;257-263.
42. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin Invest. 34:1955;1345-1353.
43. Winer J., Jung C.K., Shackel I., Williams P.M. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 270:1999;41-49.
44. SAS/STAT User's Guide, Version 6, vol. 2. 4th ed. Cary, NC: SAS Institute Inc.; 1990. p. 891-1456.
45. Saku K., Harada R., Yamamoto K., Ying H., Ozaki I., Arakawa K. Apolipoprotein Al mRNA levels in WHHL rabbits. Atherosclerosis. 84:1990;73-74.
46. Chao Y.S., Yamin T.T., Thompson G.M., Kroon P.A. Tissue-specific expression of genes encoding apolipoprotein E and apolipoprotein A-I in rabbits. J. Biol. Chem. 259:1984;5306-5309.
47. Asayama K., Hayashibe H., Dobashi K., Uchida N., Nakane T., Kodera K.et al. Increased serum cholesteryl ester transfer protein in obese children. Obes. Res. 10:2002;439-446.
48. Ebenbichler C.F., Laimer M., Kaser S., Ritsch A., Sandhofer A., Weiss H.et al. Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc. Biol. 22:2002;1465-1469.
49. Radeau T., Robb M., Lau P., Borthwick J., McPherson R. Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. Atherosclerosis. 139:1998;369-376.
50. Benoist F., Lau P., McDonnell M., boelle H., Milne R., McPherson R. Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue. J. Biol. Chem. 272:1997;23572-23577.
51. Radeau T., Lau P., Robb M., McDonnell M., Ailhaud G., McPherson R. Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J. Lipid Res. 36:1995;2552-2561.
52. Blake W.L., Ulrich R.G., Marotti K.R., Melchior G.W. The development of fatty liver is accelerated in transgenic mice expressing cynomolgus monkey cholesteryl ester transfer protein. Biochem. Biophys. Res. Commun. 205:1994;1257-1263.
53. Kobayashi J., Okamoto H., Otabe M., Bujo H., Saito Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis. 162:2002;131-135.
54. Kawano K., Qin S.C., Lin M., Tall A.R., Jiang X.C. Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo. J. Biol. Chem. 275:2000;29477-29481.
55. Jiang X.C., Masucci-Magoulas L., Mar J., Lin M., Walsh A., Breslow J.L. et al. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J. Biol. Chem. 268:1993;27406-27412.
56. Hayek T., Chajek-Shaul T., Walsh A., Agellon L.B., Moulin P., Tall A.R. et al. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-25 mediated depression of high density lipoprotein cholesterol levels. J. Clin. Invest. 90:1992;505-510.
57. Yamashita S., Hirano K., Sakai N., Matsuzawa Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim. Biophys. Acta. 1529:2000;257-275.
58. Ikewaki K., Rader D.J., Sakamoto T., Nishiwaki M., Wakimoto N., Schaefer J.R.et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-Il in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92:1993;1650-1658.
59. Yamashita S., Maruyama T., Hirano K., Sakai N., Nakajima N., Matsuzawa Y. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis. 152:2000;271-285.
60. Malchinkhuu E., Sato K., Muraki T., Ishikawa K., Kuwabara A., Okajima F. Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function. Biochem. J. 370:2003;817-827.
61. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I.et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276:2001;31780-31785.
62. Miura S.I., Fujino M., Matsuo Y., Kawamura A., Tanigawa H., Nishikawa H.et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc. Biol. 23:2003;802-808.
63. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., Tall A.R. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc. Biol. 19:1999;1105-1110.